Historical source coverage
17 selected records with a cited source date in 2009. This archive is selective and does not imply continuous monitoring or complete historical coverage.
Clinical trials · Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT00063310 at 2026-07-30T22:26:45.017Z. Its registry update date was 2009-12-11, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Regulatory · Exenatide
The official Drugs@FDA dataset lists original submission 1 for NDA 021919 with status AP dated 2009-10-30, and names exenatide synthetic among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Literature metadata · Octreotide
PeptideScanner retained PubMed bibliographic metadata for PMID 19864727 at 2026-07-30T22:27:39.979Z. PubMed recorded a metadata revision date of 2009-10-29 and an Entrez history date of 2009-10-30. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Literature metadata · Octreotide
PeptideScanner retained PubMed bibliographic metadata for PMID 19864763 at 2026-07-30T22:27:39.979Z. PubMed recorded a metadata revision date of 2009-10-29 and an Entrez history date of 2009-10-30. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Clinical trials · Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT00414973 at 2026-07-30T22:26:45.016Z. Its registry update date was 2009-10-28, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Clinical trials · Afamelanotide
PeptideScanner retained ClinicalTrials.gov record NCT00859534 at 2026-07-30T22:26:45.018Z. Its registry update date was 2009-09-15, and PeptideScanner's reviewed identity mapping was afamelanotide.
Source: ClinicalTrials.gov ↗
Clinical trials · Exenatide
PeptideScanner retained ClinicalTrials.gov record NCT00974272 at 2026-07-30T22:26:45.013Z. Its registry update date was 2009-09-10, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗
Literature metadata · Exenatide
PeptideScanner retained PubMed bibliographic metadata for PMID 19588557 at 2026-07-30T22:27:39.924Z. PubMed recorded a metadata revision date of 2009-08-04 and an Entrez history date of 2009-07-10. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Regulatory · Leuprolide
The Federal Register published notice E9-13272, attributed to FDA and its parent HHS department, on 2009-06-08. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.
Source: Federal Register via GovInfo ↗
Literature metadata · Octreotide
PeptideScanner retained PubMed bibliographic metadata for PMID 20641226 at 2026-07-30T22:27:39.988Z. PubMed recorded a metadata revision date of 2009-06-05 and an Entrez history date of 2009-06-05. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Clinical trials · Glucagon
PeptideScanner retained ClinicalTrials.gov record NCT00434772 at 2026-07-30T22:26:45.006Z. Its registry update date was 2009-05-28, and PeptideScanner's reviewed identity mapping was glucagon.
Source: ClinicalTrials.gov ↗
Literature metadata · Semax
PeptideScanner retained PubMed bibliographic metadata for PMID 19441725 at 2026-07-30T22:27:39.905Z. PubMed recorded a metadata revision date of 2009-05-15 and an Entrez history date of 2009-05-16. PeptideScanner associated this retained record with the identity slug semax. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Clinical trials · Glucagon
PeptideScanner retained ClinicalTrials.gov record NCT00817271 at 2026-07-30T22:26:45.011Z. Its registry update date was 2009-05-07, and PeptideScanner's reviewed identity mapping was glucagon.
Source: ClinicalTrials.gov ↗
Clinical trials · Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT00051558 at 2026-07-30T22:26:45.005Z. Its registry update date was 2009-03-12, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Regulatory · Liraglutide
The Federal Register published notice E9-5024, attributed to FDA and its parent HHS department, on 2009-03-10. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide.
Source: Federal Register via GovInfo ↗
Regulatory · Leuprolide
The official Drugs@FDA dataset lists original submission 1 for ANDA 078885 with status AP dated 2009-03-09, and names leuprolide acetate among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Clinical trials · Lanreotide
PeptideScanner retained ClinicalTrials.gov record NCT00565097 at 2026-07-30T22:26:45.013Z. Its registry update date was 2009-02-17, and PeptideScanner's reviewed identity mapping was lanreotide.
Source: ClinicalTrials.gov ↗